Aciphex Related Published Studies
Well-designed clinical trials related to Aciphex (Rabeprazole)
Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study. [2011.08]
Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease. [2011.06]
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. [2011.05]
An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. [2011.04]
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. [2011.01]
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. [2011.01]
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation
vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis -
the results of two double-blind studies. [2011]
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study
on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients
with non-erosive reflux disease. [2011]
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. [2010.12]
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. [2010.11]
Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. [2010.11]
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. [2010.10]
Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial. [2010.09]
Comparison of quinine and rabeprazole with quinine monotherapy in the treatment of uncomplicated falciparum malaria. [2010.09]
Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. [2010.08]
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. [2010.06]
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. [2010.05]
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. [2010.05]
Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy. [2010.03]
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. [2010.03]
Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. [2010.02]
Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects. [2010]
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in
patients with symptomatic gastro-oesophageal reflux disease - a double-blind,
placebo-controlled, randomized study. [2010]
[Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment] [2009.09.15]
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. [2009.05.01]
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. [2009.05]
Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules. [2009.04]
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. [2009.02.21]
Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers. [2009]
Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules. [2008.11.20]
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. [2008.04]
Maintenance treatment of gastroesophageal reflux disease: An evaluation of continuous and on-demand therapy with rabeprazole 20 mg. [2007.12]
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. [2007.08]
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. [2006.04.28]
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. [2006.03]
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. [2006]
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. [2005.11]
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. [2005.09.15]
A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. [2005.09]
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. [2005.08.01]
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. [2005.08]
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. [2005.07]
The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study. [2005.06.01]
Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. [2005.05.28]
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. [2005.05]
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? [2005.05]
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. [2005.05]
Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. [2005.04.01]
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. [2005.03.21]
Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. [2005.01]
Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test. [2005]
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study. [2004.12]
Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. [2004.10.15]
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. [2004.10]
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment. [2004.10]
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. [2004.10]
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? [2004.08.15]
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. [2004.07.15]
Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers. [2004.04]
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. [2004.02]
Bioequivalence study of rabeprazole sodium on healthy human volunteers. [2004.01]
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese] [2004.01]
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. [2003.12]
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. [2003.12]
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. [2003.12]
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. [2003.11.15]
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. [2003.11.01]
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. [2003.11]
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. [2003.11]
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. [2003.09]
Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? [2003.09]
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. [2003.07.01]
Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. [2003.07]
Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. [2003.05.01]
Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. [2003.04]
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. [2003.04]
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. [2003.03.15]
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. [2003.02.15]
Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. [2003.02]
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. [2003.02]
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. [2003.01]
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. [2003.01]
[Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors] [2003]
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. [2003]
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. [2002.11]
Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. [2002.07]
The efficacy of lafutidine in improving preoperative gastric fluid property: a comparison with ranitidine and rabeprazole. [2002.07]
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. [2002.06]
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. [2002.03]
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. [2002]
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole. [2002]
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. [2001.12]
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. [2001.11]
Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. [2001.09]
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. [2001.09]
Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. [2001.09]
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. [2001.07]
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. [2001.06]
Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. [2000.12]
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. [2000.12]
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. [2000.11]
|
